Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya

• Published in: BMC infectious diseases Vol. 22; no. 1; pp. 73 - 15
• Main Authors: Sambai, Betsy C, Kingston, Hanley, Monroe-Wise, Aliza, Mbogo, Loice, Juma, Emily, Ludwig-Barron, Natasha, Guthrie, Brandon L, Bukusi, David, Chohan, Bhavna H, Scott, John, Bosire, Rose, Dunbar, Matthew, Macharia, Paul, Masyuko, Sarah, Sinkele, William, Herbeck, Joshua T, Farquhar, Carey
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21-01-2022; BioMed Central; BMC
• Subjects: Advisors; Antibodies; Clustering; Coasts; Cross-Sectional Studies; Demographic aspects; Distribution; Drug use; Drug Users; Drugs; Enrollments; Female; Females; Hepacivirus; Hepatitis; Hepatitis C; Hepatitis C (HCV); Hepatitis C - epidemiology; Heroin; HIV; HIV infection; HIV Infections - complications; HIV Infections - epidemiology; Human immunodeficiency virus; Humans; Infections; Infectious diseases; Kenya - epidemiology; Male; Persons who inject drugs (PWID); Pharmaceutical Preparations; Prevalence; Regions; Risk factors; Risk-Taking; Seroepidemiologic Studies; Serology; Sex; Sexually transmitted diseases; STD; Sub-Saharan Africa (SSA); Substance Abuse, Intravenous - complications; Substance Abuse, Intravenous - epidemiology; Kenya; Africa; Hepatitis C (HCV); Sub-Saharan Africa (SSA); HIV; Persons who inject drugs (PWID)
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-022-07036-8

Persons who inject drugs (PWID) have higher HIV and hepatitis C virus (HCV) seroprevalence than the general population in many parts of sub-Saharan Africa (SSA). The seroprevalences of HIV and HCV are also higher in coastal Kenya than in Nairobi. Understanding drivers of regional HIV and HCV variation among PWID in Kenya may inform population-specific prevention interventions.
Using a cross-sectional study, we defined HIV and HCV seroprevalence among persons identified as sexual or injecting partners of HIV positive PWID in two regions of Kenya and used logistic regression to identify demographic and behavioral characteristics associated with higher seroprevalence.
Among 2386 partners, 469 (19.7%) tested HIV positive and 297(12.4%) tested HCV antibody positive. Partners on the Coast were more likely to live with HIV (seroprevalences: Coast = 23.8%, Nairobi = 17.1%; p < 0.001) and be HCV antibody positive (seroprevalences: Coast = 17.0%, Nairobi = 8.6%; p < 0.001). After adjusting for sex, age, and years injecting and accounting for clustering by site, the higher prevalence of both diseases in the Coast remained significant for HIV (OR 1.68, 95% CI 1.13-2.51) but not for HCV (OR 1.72, 95% CI 0.84-3.74). Compared to those recruited in Nairobi, partners on the Coast were older (Coast = 35 years, Nairobi = 31 years; p < 0.001), more likely to be male (Coast = 77.6%, Nairobi = 61.7%; p < 0.001), to have paid (Coast = 59.2%, Nairobi = 32.8%; p < 0.001) or received (Coast = 44.2%, Nairobi 35.4%; p < 0.001) money for sex, or to have had sex with someone they knew to be HIV positive (Coast 22.0%, Nairobi 10.8%; p < 0.001). Partners who had injected for five or more years had 1.48 times greater odds (95% CI 1.20-1.82) of living with HIV compared to partners who injected less than 5 years and more than twice the odds of HCV (95% CI 1.84-4.11).
HIV and HCV seroprevalence among sexual and injecting partners of PWID was, respectively, 5 times and > 12 times greater than is reported among the general population in Kenya (4% and < 1%, respectively). Providing resources and education will be crucial to reduce exposure and to maintain the lower needle and equipment sharing that we observed compared to other studies.